Basel Medical Group Announces 1-for-12 Reverse Stock Split to Maintain Nasdaq Listing
BMGL sits 62% above its 52-week low of $0.383 on light trading volume (0.2× avg).
Summary
Basel Medical Group Ltd. will implement a 1-for-12 reverse stock split on June 22, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
Key Events · Corporate Governance and Compliance · BMGL
-
Reverse Stock Split Approved
The board of directors has approved a 1-for-12 reverse stock split of the company's issued and outstanding shares.
-
Nasdaq Compliance Objective
The primary goal of the reverse split is to re-comply with Nasdaq Marketplace Rule 5550(a)(2), which mandates a minimum bid price of $1 per share.
-
Effective Date
The reverse share split will become effective with the opening of trading on June 22, 2026.
-
Share Count Reduction
The number of outstanding ordinary shares will be reduced from 18,785,750 to approximately 1,565,480, subject to rounding.
Analysis · BMGL · Industrial Applications And Services
Basel Medical Group is implementing a reverse stock split to meet Nasdaq's minimum bid price requirement, a common action for companies facing potential delisting. While necessary for continued listing, such moves often signal underlying financial or operational challenges and can lead to increased investor skepticism. For a micro-cap company, this event highlights the precarious position and the need to address fundamental business performance.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 997 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMGL was trading at $0.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12M. The 52-week trading range was $0.38 to $5.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.